This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HomeHomeVaccines HomepageDisease AreasDisease AreasRespiratory Syncytial Virus (RSV)Pneumococcal diseaseTick-borne encephalitis (TBE)Meningococcal diseaseOur BrandsOur BrandsABRYSVO®▼ (respiratory syncytial virus vaccine (bivalent, recombinant))APEXXNAR®▼ (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed))Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine)Trumenba®▼ (meningococcal group B vaccine (recombinant, adsorbed))Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed))TicoVac® (tick-borne encephalitis vaccine (whole virus inactivated))Vaccine TechnologiesVaccine TechnologiesMaternal ImmunisationConjugate TechnologyPolysaccharide VaccinesInactivated VaccinesSupport & ResourcesSupport & ResourcesClinic support materials

ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Prescribing Information can be found here.

Respiratory Syncytial Virus (RSV)Uncover the hidden annual epidemic1 How does RSV affect your patients?Hear about this unknown 'annual healthcare distaster' from Dr Openshaw, Dr Englund, Dr Walsh and Dr Gonik.1

Understand how RSV (using influenza as a comparator) and the serious consequences for certain populations including young infants and older adults.2,3,4

ButtonLoading~3 minute watchHear one family's story about a serious RSV infection. This is Justice and Weston's Story.

One of the approximately 64 million acute respiratory infections that occur each year across the globe.5

Click to download the maternal discussion guide
Loading

Learn from Global Experts about the symptoms, transmision & burden of RSV infection, and how it could affect your patients with our RSV Expert video series.

Introducing the Global Experts on RSV...Peter Openshaw, MD, PhD Edward Walsh, MD Janet Englund, MD Bernard Gonik, MD The What, Who and How of RSV
What is RSV and how is it transmitted?
 Uncover RSV and how it is transmitted.

Although it gets less attention than influenza, RSV is highly contagious and can be spread by asymptomatic carriers.2,3,6

Learn more about how long RSV can survive on different surfaces, the incubation period, symptom presentation and the occurance of viral shedding with Dr Openshaw, Dr Englund and Dr Walsh.3,7

Everyone is susceptible to an RSV infection, but who is most at risk?2
Uncover who is most at risk of serious outcomes from an RSV infection. 

The RSV Experts share about the fleeting natural immunity to RSV and the commonality of reinfection, with a focus on why infants and older adults are more susceptible to serious outcomes of an RSV infection.4

They expand on differing immune responses and physical characteristics in these populations to explain this increased susceptibility.3,4

The hidden annual epidemic with ~64 million global cases each year.5 
Hear more from the experts...

~2 minute watch

Find out how this affects global healthcare systems and hospitalisation of patients in the UK.

~2 minute watch

Symptoms of an RSV infection can vary widely and are most severe at the extremes of age.4,8

Useful Resources

 Learn more about ABRYSVO®▼

Discover how to protect your patients with our RSV vaccine for both maternal and older adult indications. eModules now available.

 Click here for more about ABRYSVO®Loading Start conversations with your patients

A guide to help you make the most out of your next maternal immunisation conversation.

Click here for our discussion guideLoading

References:

National Foundation for Infectious Diseases. RSV: The Annual Epidemic You May Not Know About (But Should). National Foundation for Infectious Diseases (online). Updated: 30 November 2016. Accessed: February 2024. https://www.nfid.org/rsv-the-annual-epidemic-you-may-not-know-about-but-should/RSV transmission. Centers for Disease Control and Prevention. Updated April 26, 2023. Accessed February 2024. https://www.cdc.gov/rsv/about/transmission.htmlCarvajal JJ, Avellaneda AM, Salazar-Ardiles C, Maya JE, Kalergis AM, Lay MK. Host components contributing to respiratory syncytial virus pathogenesis. Front Immunol. 2019;10(2152):1-19.Talbot HK, Belongia EA, Walsh EE, Schaffner W. Respiratory syncytial virus in older adults: a hidden annual epidemic. Infect Dis Clin Pract. 2016;24(6):295-302.Hartnett J, Donga P, Ispas G, et al. Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study. Influenza Other Respir Viruses. 2022;16(5):906-915.Hall CB. Nosocomial respiratory syncytial virus infections: the “cold war” has not ended. Clin Infect Dis. 2000;31(2):590-596.Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75-85.RSV in older adults and adults with chronic medical conditions. Centers for Disease Control and Prevention. Updated November 7, 2023. Accessed February 2024. https://www.cdc.gov/rsv/high-risk/older-adults.html
PP-A1G-GBR-0171. August 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​